Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 2/20 | 0.48 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.48 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.48 |
| ▸ | FAP | Q12884 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5597620 | 1.00 | OPRM1 (0.49) | OPRM1OPRD1F2OPRK1DPP4 | |
| SCHEMBL7418654 | 1.00 | OPRM1 (0.49) | OPRM1OPRD1F2OPRK1DPP4 | |
| SCHEMBL5597616 | 1.00 | OPRM1 (0.49) | OPRM1OPRD1F2OPRK1DPP4 | |
| SCHEMBL2182404 | 0.97 | F2 (0.47) | OPRM1OPRD1F2OPRK1DPP4 | |
| SCHEMBL7207928 | 0.90 | OPRM1 (0.51) | OPRM1F2OPRK1 | |
| SCHEMBL2193283 | 0.89 | OPRM1 (0.48) | OPRM1OPRD1OPRK1 | |
| SCHEMBL9280512 | 0.89 | XIAP (0.48) | OPRM1F2OPRK1 | |
| SCHEMBL2778546 | 0.88 | F2 (0.57) | OPRM1OPRD1F2OPRK1 | |
| SCHEMBL6497247 | 0.88 | F2 (0.57) | OPRM1OPRD1F2OPRK1 | |
| SCHEMBL6850160 | 0.88 | F2 (0.57) | OPRM1OPRD1F2OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4505852-A | 7-Amino-4-trifluoromethylquinolone derived substrates and method for determining enzymes and inhibitors | ENZYME SYSTEMS PRODUCTS (US) | 1985-03-19 | — | — | US | claimed |
| US-20190070251-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2019-03-07 | — | — | US | disclosed |
| US-9682153-B2 | Polymer conjugates of therapeutic peptides | NEKTAR THERAPEUTICS (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2016-01-28 | — | — | US | disclosed |
| US-9173951-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150051371-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2015-02-19 | — | — | US | disclosed |
| US-8680263-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2014-03-25 | — | — | US | disclosed |
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
| CN-1039125-C | Amidinophenylalanine derivatives and process for preparing same and use | REHRINGWERKE AG (DE) | 1998-07-15 | — | — | CN | disclosed |
| EP-0724446-A4 | ELECTROPHILIC PEPTIDE ANALOGS AS INHIBITORS OF TRYPSIN-LIKE ENZYMES | DU PONT MERCK PHARMA (US) | 1998-01-07 | — | — | EP | disclosed |
| CN-1169730-A | Aromatic heterocyclic derivatives as enzyme inhibitors | CORVAS INT INC (US) | 1998-01-07 | — | — | CN | disclosed |
| US-5639739-A | USEFUL FOR TREATING THROMBOSIS IN MAMMALS BY INHIBITING TRYPSIN-LIKE SERINE PROTEASE ENZYMES | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-06-17 | — | — | US | disclosed |
| CN-1151166-A | 3-Amino-2-oxo-1-piperidineacetic acid derivatives as enzyme inhibitors | CORVAS INT INC (US) | 1997-06-04 | — | — | CN | disclosed |
| EP-0724446-A1 | ELECTROPHILIC PEPTIDE ANALOGS AS INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-08-07 | — | — | EP | disclosed |
| CN-1121068-A | Prolinamide derivatives | MITSUBISHI CHEM CORP (JP) | 1996-04-24 | — | — | CN | disclosed |
| WO-1995009634-A1 | ELECTROPHILIC PEPTIDE ANALOGS AS INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-04-13 | — | — | WO | disclosed |
| CN-1067249-A | Amidinophenylalaninederivatives derivatives and Preparation Method And The Use | BEHRINGWERKE AG (DE) | 1992-12-23 | — | — | CN | disclosed |
| US-4505852-A | 7-Amino-4-trifluoromethylquinolone derived substrates and method for determining enzymes and inhibitors | ENZYME SYSTEMS PRODUCTS (US) | 1985-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | OPRM1 2317/4885OPRD1 3100/4885F2 2099/4885 |
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | OPRM1 3352/4885OPRD1 3859/4885F2 3457/4885 |
| US-20150051371-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | OPRM1 3352/4885OPRD1 3859/4885F2 3457/4885 |
| US-20190070251-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | OPRM1 2317/4885OPRD1 3100/4885F2 2099/4885 |
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | DNPEP, VIP, PTMS | OPRM1 1535/4885OPRD1 2871/4885F2 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.